Tyrosine kinase inhibitorFDA-approvedSecond-line
Palbociclib
How it works
Blocks the CDK4/6 enzymes that drive cell division in cancer cells, allowing the body's natural repair mechanisms to take over.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Studies have shown that palbociclib can improve progression-free survival and overall survival in patients with hormone receptor-positive breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Using Text Messages to Help People Take Palbociclib for Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Testing Palbociclib and Binimetinib in RAS-Mutant Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| New Long-Acting Palbociclib Injection for Metastatic Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Palbociclib in Metastatic Prostate Cancer: A Clinical Trial | Prostate Cancer | phase-2 | — | Source → |
| Lab Test Models Breast Cancer Cells to Study Palbociclib Effectiveness | Breast Cancer | lab-study | — | Source → |
| New Insights into Treating Low-Grade Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Palbociclib and Neutropenia in Metastatic Breast Cancer | Breast Cancer | observational | The 30-month PFS rate was 75% with the dose of 100 mg, 90.9% with 75 mg, and 97.2% with the dose of 125 mg. | Source → |
| Palbociclib's Potential in Leukemia Treatment | Leukemia | review | — | Source → |
| Palbociclib Effectiveness in Indian Breast Cancer Patients | Breast Cancer | observational | The real-world response rate and the real-world clinical benefit rate across treatment lines were 68% and 75.3%, respectively. | Source → |
| Intermittent Palbociclib Use in Metastatic Breast Cancer During Economic Crisis | Breast Cancer | observational | Intermittent discontinuation statistically reduces PFS by 26%. | Source → |
| Real-world effectiveness of palbociclib in breast cancer treatment | Breast Cancer | meta-analysis | First-line palbociclib+AI MMPFS (22.5 months, 95% CI = 19.5 to 31.8) aligned with PALOMA-1/2 pooled mPFS (23.9, 95% CI = 20.2 to 27.6). | Source → |
| Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japan | Breast Cancer | observational | The median progression-free survival was 26.6 months. | Source → |
| Comparing Two Cancer Treatments in Younger Women | Breast Cancer | observational | The median progression-free survival was 24.05 months for palbociclib and 24.41 months for ribociclib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.